Xintela - Approaching major milestones
Xintela’s Q321 report provides key updates on the company’s pipeline and business plans. Lead programme XSTEM-OA will begin patient enrolment in early 2022, with the aim of showing disease-modifying osteoarthritis drug (DMOAD) properties. A second clinical study, assessing XSTEM in difficult-to-heal venous leg ulcers, is planned for mid-2022 and offers a potentially faster path to market. Subsidiary Targinta has advanced towards preclinical development following selection of a drug candidate (TARG10) for triple negative breast cancer (TNBC) with spin-off formalities picking up speed. We expect several potential inflection points for Xintela in coming months, albeit contingent on sufficient and timely fund-raising.Xintela AB (Xintela) is a Sweden-based biomedical company engaged in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumors. In the field of regenerative medicine, the Company focuses on cartilage damage and osteoarthritis, and in the field of brain tumors, its focuses on the development of a treatment for glioblastoma, an aggressive tumor. The Company has developed therapeutic antibodies, which bind to cancer cells. It has also developed XINMARK, a marker technology which consists of specific proteins, which work as recognition flags on the surface of certain cells. The markers make it possible to identify and select certain types of stem cells which can develop into cartilage cells.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.